Form 4: Replimune Director Receives Significant Equity Grants

Director Philip Astley-Sparke was awarded 50,000 restricted stock units and 75,000 stock options as part of Replimune Group's compensation structure.

Summary

• Philip Astley-Sparke, a Director at Replimune Group, Inc., received two separate equity awards on April 1, 2026.
• The first award consists of 50,000 Restricted Stock Units (RSUs), which represent a contingent right to receive common stock at no cost upon vesting.
• The second award consists of 75,000 stock options with an exercise price of $7.61 per share.
• The RSUs follow a four-year vesting schedule, with the first 25% vesting on May 15, 2027, and the remainder vesting annually through May 15, 2030.
• The stock options also follow a four-year vesting schedule, with 25% vesting on April 1, 2027, followed by 36 equal monthly installments.
• Following these transactions, the reporting person directly owns 1,430,071 shares of common stock and 75,000 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the high level of insider ownership and long-term vesting, though the administrative filing delay is a minor negative.

Positives

• The Director maintains a substantial direct ownership stake of over 1.4 million shares, indicating strong alignment with shareholder interests.
• The multi-year vesting schedules (extending to 2030) incentivize long-term commitment and performance.
• The exercise price for the options is set at $7.61, providing a clear benchmark for future value creation.

Negatives

• The filing was submitted late, which management attributed to an inadvertent administrative error.
• The issuance of new equity units and options will result in future dilution for existing shareholders.

Risks

• Potential for share price dilution as 125,000 new shares are eventually issued upon vesting and exercise.
• Administrative oversight leading to late SEC filings can occasionally signal internal control weaknesses, though this instance is described as a one-time error.

Future Outlook

The long-term vesting schedules suggest that the Director is expected to remain with the company through at least 2030 to fully realize the value of these equity grants.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, heavy reliance on equity-based compensation for directors and executives is standard practice to conserve cash for clinical trials while aligning leadership with long-term stock performance.

Comparison to Industry Standards

• The grant size is consistent with mid-cap biotechnology board compensation packages.
• The four-year vesting period is a standard industry benchmark for executive and director retention.
• The use of both RSUs and stock options is a common 'balanced' approach to incentive-based pay in high-growth sectors.

Corporate Governance

Related Party Transactions

• The issuance of 50,000 RSUs and 75,000 stock options to Director Philip Astley-Sparke constitutes a related party transaction under executive compensation disclosure rules.

Stakeholder Impact

• Shareholders: Experience minor potential dilution from the 125,000 new equity instruments.
• Management/Board: Philip Astley-Sparke receives increased financial incentive tied to company performance.

Next Steps

• Vesting of the first tranche of options on April 1, 2027.
• Vesting of the first tranche of RSUs on May 15, 2027.

Key Dates

Recommendation

This is a routine administrative filing for director compensation. While the insider ownership is high, which is a positive sign, the filing itself does not provide new material information regarding the company's clinical progress or financial health that would warrant a change in investment thesis.

Keywords

Replimune Group, REPL, Insider Trading, Form 4, Philip Astley-Sparke, Stock Options, Restricted Stock Units, Director Compensation, Biotechnology